Shah ASV, et al.N Engl J Med. 2021 Sep 8:NEJMc2106757. doi: 10.1056/NEJMc2106757. Online ahead of print.N Engl J Med. 2021.PMID: 34496200
.
Health and Clinical Management.
Monga B.Monga B.Yearb Med Inform. 2004;(1):269-271.
.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
.
. Dagan N, et al.Nat Med. 2021 Sep 7. doi: 10.1038/s41591-021-01490-8. Online ahead of print.Nat Med. 2021.PMID: 34493859
.
. Haider N, et al.J Clin Invest. 2021 Sep 10:151818. doi: 10.1172/JCI151818. Online ahead of print.J Clin Invest. 2021.PMID: 34506305
. Zhang W, et al.N Engl J Med. 2021 Aug 30. doi: 10.1056/NEJMoa2111437. Online ahead of print.N Engl J Med. 2021.PMID: 34491661
.